Stryker Acquires Amplitude Vascular Systems for Next-Gen IVL Technology — Stryker Corporation

Event summary

Stryker has signed a definitive agreement to acquire Amplitude Vascular Systems (AVS), a privately held medical technology company specializing in next-generation intravascular lithotripsy (IVL) platforms for treating calcified peripheral arterial disease.
The acquisition aims to strengthen Stryker’s Peripheral Vascular portfolio by adding AVS’ IVL technology, which uses pulsed CO₂-generated pressure waves to fracture calcium and optimize luminal gain.
AVS was founded in 2017 by Hitinder Gurm, M.D., and Robert Chisena, Ph.D., and is backed by investors including BioStar Capital and Cue Growth Partners.

The big picture

The acquisition aligns with Stryker’s strategy to build a comprehensive peripheral vascular platform, addressing significant unmet clinical needs in calcified arterial disease. IVL technology is experiencing strong growth as physicians adopt calcium modification in complex procedures, positioning Stryker to capitalize on this trend.

What we're watching

Regulatory Approval: The pace at which AVS’ IVL technology receives regulatory clearance in applicable markets will determine the speed of integration and commercialization within Stryker’s portfolio.
Market Expansion: Whether Stryker can leverage AVS’ technology to expand its presence in treating calcified peripheral arterial disease, a fast-growing segment within cardiovascular intervention.
Integration Strategy: How Stryker plans to integrate AVS’ innovation with its existing Peripheral Vascular offerings and scale its clinical expertise to enhance treatment options for physicians.